Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Reducing the global burden of HTLV-1 infection: An agenda for research and action

ACCOLLA, ROBERTO;Ciminale, Vincenzo;GALLO, ROBERT CHARLES;
2017-01-01

Abstract

Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
2017
www.elsevier.com/locate/antiviral
HTLV-1; Leukemia; Oncogene; Retrovirus; Vaccine; Pharmacology; Virology
Willems, Luc; Hasegawa, Hideki; Accolla, Roberto; Bangham, Charles; Bazarbachi, Ali; Bertazzoni, Umberto; Carneiro Proietti, Anna Barbara de Freitas; Cheng, Hua; Chieco Bianchi, Luigi; Ciminale, Vincenzo; Coelho dos Reis, Jordana; Esparza, José; Gallo, ROBERT CHARLES; Gessain, Antoine; Gotuzzo, Eduardo; Hall, William; Harford, Joseph; Hermine, Olivier; Jacobson, Steven; Macchi, Beatrice; Macpherson, Calum; Mahieux, Renaud; Matsuoka, Masao; Murphy, Edward; Peloponese, Jean Marie; Simon, Viviana; Tagaya, Yutaka; Taylor, Graham P.; Watanabe, Toshiki; Yamano, Yoshihisa
File in questo prodotto:
File Dimensione Formato  
Willems et al, Antiviral Research 2017.pdf

non disponibili

Descrizione: pdf
Tipologia: Versione Editoriale (PDF)
Licenza: DRM non definito
Dimensione 1.71 MB
Formato Adobe PDF
1.71 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2061478
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 96
social impact